Provided by Tiger Trade Technology Pte. Ltd.

Beyondspring Inc

0.7199
-0.0002-0.03%
Volume:21.10K
Turnover:14.91K
Market Cap:29.60M
PE:-4.23
High:0.7224
Open:0.7003
Low:0.7003
Close:0.7201
52wk High:2.44
52wk Low:0.6699
Shares:41.12M
Float Shares:30.79M
Volume Ratio:0.28
T/O Rate:0.07%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1700
EPS(LYR):-0.0249
ROE:-310.48%
ROA:-22.86%
PB:-0.83
PE(LYR):-28.92

Loading ...

BeyondSpring Posts Investor Deck Highlighting Plinabulin Late-Stage NSCLC Program and Immune-Modulating Approach

Reuters
·
Aug 16

BeyondSpring Q2 EPS $(0.02) Up From $(0.04) YoY

Benzinga Earnings
·
Aug 15

Beyondspring Reports Second-Quarter 2026 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
Aug 15

NASDAQ Trade Halt Volatility Trading Pause at 12:21 Pm

Reuters
·
Aug 14

Beyondspring Posts Corporate Presentation Spotlighting Plinabulin Immune-modulating Cancer Therapy Pipeline

Reuters
·
Jul 10

Beyondspring Files Form 3 for CFO Na Li Showing no Beneficial Ownership

Reuters
·
Jul 07

Beyondspring Amends Filing to Disclose CEO Min Qiu Pay Package, Including USD 100,000 Salary

Reuters
·
Jun 30

BeyondSpring names Min Qiu CEO in leadership transition effective July 1, 2026

Reuters
·
Jun 04

Beyondspring - Appoints Jiangwen (Jen) Majeti as Vice Chairman

THOMSON REUTERS
·
Jun 04

Beyondspring - Appoints Na Li as Chief Financial Officer

THOMSON REUTERS
·
Jun 04

Beyondspring - Appoints Min Qiu as Chief Executive Officer

THOMSON REUTERS
·
Jun 04

Beyondspring - Lan Huang Remains Chairman of Beyondspring, Focuses Executive Duties on Seed Therapeutics

THOMSON REUTERS
·
Jun 04

Beyondspring Announces Leadership Transition to Deliver Focused Execution on Its Confirmatory Dublin-4 Program and Long-Term Value

THOMSON REUTERS
·
Jun 04

Press Release: BeyondSpring Announces Leadership Transition to Deliver Focused Execution on Its Confirmatory DUBLIN-4 Program and Long-Term Value

Dow Jones
·
Jun 04

BeyondSpring publishes corporate deck highlighting plinabulin immune-modulating cancer therapy pipeline

Reuters
·
Jun 03

Beyondspring - Reports 12-Month Os Rate of 78.1%, 24-Month Os Rate of 58% in Phase 2 Nsclc Study

THOMSON REUTERS
·
Jun 02

Beyondspring - 53.2% of Patients Experienced Grade 3 or Higher Adverse Events in Phase 2 Nsclc Study

THOMSON REUTERS
·
Jun 02

Beyondspring - Reports Median Pfs of 7 Months, Dcr of 79.5% in Phase 2 Nsclc Study

THOMSON REUTERS
·
Jun 02

BeyondSpring says Phase 2 trial shows 7-month median PFS for pembrolizumab plus plinabulin/docetaxel in post-ICI metastatic NSCLC

Reuters
·
Jun 02

BeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune Checkpoint Inhibitor Therapy at ASCO 2026

GlobeNewswire
·
Jun 02